Possible Biomarkers for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Immune checkpoint inhibitors (ICIs) have transformed cancer care but benefit a limited patient population.
• Predictive biomarkers are essential to identify patients likely to respond to ICIs and manage treatment costs and adverse events.
• Current biomarkers, such as programmed cell death-ligand 1 (PD-L1) expression, have limitations due to variability and heterogeneity.

Purpose of the Study:

• To review recent clinical literature on potential biomarkers for predicting response to cancer immunotherapy.
• To highlight emerging biomarkers beyond PD-L1, including tumor mutational burden, neoantigens, mismatch repair status, gene mutations, and fecal microbiota.
• To emphasize the need for a predictive model integrating multiple biomarkers for precision cancer immunotherapy.

Main Methods:

• Literature review of recent clinical articles focusing on biomarkers for cancer immunotherapy.
• Analysis of studies investigating programmed cell death-ligand 1 (PD-L1) expression as a predictive marker.
• Examination of emerging biomarkers such as tumor mutational burden, neoantigens, mismatch repair status, gene mutations, and fecal microbiota.

Main Results:

• Programmed cell death-ligand 1 (PD-L1) expression remains a potential biomarker but faces challenges with definition and heterogeneity.
• Tumor mutational burden, neoantigen expression, mismatch repair status, and specific gene mutations are emerging as promising indicators of ICI response.
• Fecal microbiota composition prior to immunotherapy may significantly influence treatment efficacy.

Conclusions:

• A combination of biomarkers, including PD-L1, tumor characteristics, and gut microbiome, is likely needed for accurate prediction of immunotherapy response.
• Further research is required to develop a comprehensive predictive model for precision medicine in cancer immunotherapy.
• Integrating diverse biomarkers will enhance patient selection for ICIs, optimizing treatment outcomes and minimizing adverse events.